Original from: business wire

CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy today announced the successful completion of its previously announced acquisition of Naveris, following the satisfaction of all closing conditions. The transaction terms were disclosed at the time of announcement in April 2026.

Naveris’s lead product, NavDx, is a blood-based test that detects and monitors viral-mediated cancers — including human papillomavirus (HPV)-associated head and neck and anal cancers — from diagnosis through post-treatment molecular residual disease (MRD) surveillance. NavDx is the first and only Medicare-covered assay for HPV-driven head and neck and anal cancer MRD.

Over 130,000 NavDx tests have been commercially reported to date. The test first obtained Medicare coverage in 2023 and has an ADLT Medicare reimbursement rate of $1,800. In 2025, Naveris generated approximately $35 million in revenue, more than doubling year-over-year. CareDx now offers a portfolio of precision diagnostic testing services across solid organ transplant, cell therapy-based hematologic malignancies, and viral-mediated cancers, addressing a U.S. market that is now estimated to exceed $12 billion.

"CareDx wins by commercializing category-leading, repeat molecular biomarker testing for patients with a high burden of disease — that's our growth model," said John Hanna, President and Chief Executive Officer of CareDx. "NavDx fits that model precisely. We believe we have the platform and the focus to scale it, and we expect it to be a meaningful contributor to CareDx’s growth from day one."

Beginning in the third quarter of 2026, Naveris will be included in CareDx’s consolidated financial results.

Source: CareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty Oncology